When REVEAL meets AMBITION, does it reveal more?

The first registry of patients with pulmonary arterial hypertension (PAH), established by the US National Heart, Lung, and Blood Institute (NHLBI) in 1981, reported a median survival of 2.8 years in the empirical therapy era.1 Shortly after bosentan was approved in the early 2000s, the French registry reported a one-year survival of 88% in patients with PAH,2 while the Chinese registry reported 1,3, and 5-year survivals of 68%, 38.9%, and 20.8% respectively, in patients with idiopathic and familial PAH who were treated with conventional therapies.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Invited Commentary Source Type: research